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objects. This, and the common need for distance vision correc-
tion, often results in the use of eyeglasses. The objectives of this
survey were to collect data in ﬁve European countries (France,
Germany, Italy, Spain and the UK) on the associated societal costs
of wearing spectacles and subject willingness to pay to be free of
spectacles. METHODS: A sample of citizens over 45 years of age
and wearing glasses was selected using a quota method (age,
gender, occupation). Telephone interviews (22 questions) were
conducted using a Computer Aided Telephone Interviewing
system. RESULTS: A total of 4157 subjects were interviewed
across the countries. 38.4% were >65 years old and 55.8% were
female. In all countries, prescribed glasses were mainly mono-
focal (49.7–72.8%), except for France (29.8%). Spectacles were
replaced every 2 or more years by 70.4% of the subjects and the
average expenditure exceeded €145 per pair in 62.9% of the
cases. Replacement frequency was higher in the UK and expen-
ditures were higher in France. The 3 main daily tasks requiring
glasses were reading (60.4%), watching TV (33.6%) and shop-
ping (28.8%). Across all the countries, 45.3% of the subjects
declared that they would be willing to pay at least a part of the
cost to avoid spectacles. Men and people less than 64 years old
had a higher willingness to pay to be free of spectacles. CON-
CLUSION: Citizens living in a country where private insurance
reimburses a signiﬁcant portion of eyeglass costs bought more
expensive spectacles. A higher spectacle replacement frequency is
associated with a lower price. About half the European citizens
would be willing to pay at least a part of the cost to be free of
spectacles, especially men and people <64 years of age.
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OBJECTIVES: Develop a health economic model to measure the
standard of care costs in the UK (UK) associated with progres-
sion of primary open angle glaucoma. METHODS: We used
Monte Carlo techniques to model the cost of a simulated cohort
of 600 patients with Mean Deviation (MD) score progression
over four years. MD scores were used to estimate resource utili-
zation for the cohort using regression equations from an analysis
of the relationship between resources and MD score in the worst
eye from a European chart review of glaucoma patients (N = 194
from UK, Italy, France, Germany and Austria). Both medical
(number of ofﬁce visits, visual ﬁeld exams, trabeculoplasties and
trabeculectomies) and pharmacy resources (number of glaucoma
medications) were included in the model. UK NHS reference
costs were applied to the medical resource utilization estimates;
medication costs from the British National Formulary were
applied to the pharmacy utilization estimates. MD scores were
also used to predict utility scores based on a regression analysis
of utility scores among glaucoma patients in Sweden; the quality-
adjusted-life years (QALYs) over four years was modeled. A
probabilistic sensitivity analysis was also performed. RESULTS:
The four-year cost for the cohort was 932 per patient (196 in
pharmacy costs and 736 in medical costs) with 2.96 QALYs
accumulated over four years. CONCLUSION: Glaucoma pro-
gression as evidenced by worsening MD scores is associated with
a loss in quality of life and substantial costs over four years of
follow-up. Managing the disease and delaying progression has
the potential to improve quality of life and reduce costs among
patients with progression.
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OBJECTIVES: Study the oxidative status in patients with
primary open-angle glaucoma (POAG) in order to evaluate
if antioxidant supplementation may beneﬁt these patients.
METHODS: Enzimatic-colorimetric biochemical assays for
determining peroxidative (malondialdehyde, MDA), antioxidant
(total antioxidan statust TAS) and nitrosative (nitric oxide, NO)
activities were carried out in the aqueous humour from one
hundred and twenty patients operated alternatively for primary
open angle glaucoma (POAG-G) or cataracts (CAT-G). A com-
parison between groups was done by using the Student T test by
means of the SPSS statistical package. RESULTS: The MDA
levels were signiﬁcantly higher (p < 0.001) in the aqueous
humour from the POAG-G than in the CAT-G. The TAS levels
were signiﬁcantly lower (p < 0.01) in the POAG-G samples than
in the comparative ones. NO levels were signiﬁcantly higher
(p < 0.05) in the POAG-G samples than in the CAT-C. CON-
CLUSION: The relationship between pro-oxidant and antioxi-
dant activities in the aqueous humour was strongly dysbalanced
towards oxidative capacity in the glaucoma patients. All data
suggest that oxidative stress has to be considered among the
etiopathogenical mechanisms of advanced glaucoma. The possi-
bility remains that antioxidant supplementation may beneﬁt the
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OBJECTIVES: To estimate the net health beneﬁts of intravitreal
VEGF inhibitors indicated for patients with NV-AMD with dif-
fering baseline risks for cardiovascular events. METHODS: A
decision-analytic risk-beneﬁt model with a 10-year horizon was
developed to jointly assess the intended and unintended effects of
pegaptanib and of ranibizumab. Input data were abstracted from
the results of published randomized controlled trials comparing
active comparator to usual care (UC). Intended effects of treat-
ment were quantiﬁed using the relative risk (RR) of progression
to legal blindness (<20/200 visual acuity [VA]) in the better
seeing-eye. Unintended effects included key Anti-Platelet Trial-
ists’ Collaborative events (APTC: fatal or non-fatal myocardial
infarction, cerebrovascular accident, or death from unknown
or vascular cause) or severe non-ocular hemorrhages (NOH).
Ranibizumab treatment was associated with RRs of 0.27 (pro-
gression to legal blindness; 95% conﬁdence interval: 0.21–0.36),
2.2 (APTC events; 0.78–6.30) and 5.5 (severe NOH; 0.7–46.3).
Pegaptanib was associated with RRs of 0.65 (progression to legal
blindness; 0.54–0.79), 1.5 (APTC events; 0.4–5.3) and 0.8
Abstracts A349
